M. Amér

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

C. Craddock, C. Crawley, M. Dennis, 2021, Blood.

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

N. Potter, C. Craddock, N. Russell, 2022, Blood.

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

N. Potter, C. Crawley, A. Wei, 2022, Blood.

Comprar Design, Execution, and Management of Medical Device Clinical Trials | M. S. Amer | 9780470474266 | Wiley

M. S. Amer, Salah Abdel-aleem, S. Abdel-aleem, 2009 .

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

N. Potter, C. Craddock, N. Russell, 2023, Leukemia.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy.

N. Potter, C. Crawley, N. Russell, 2023, Blood.